ADMA Biologics, Inc. logo ADMA - ADMA Biologics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 1
BUY 8
HOLD 1
SELL 0
STRONG
SELL 0
| PRICE TARGET: $18.67 DETAILS
HIGH: $21.00
LOW: $17.00
MEDIAN: $18.00
CONSENSUS: $18.67
UPSIDE: 111.92%

Stock News

ADMA INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead ADMA Biologics Class Action Lawsuit

ADMA INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead ADMA Biologics Class Action Lawsuit

SAN DIEGO, July 17, 2026 /PRNewswire/ --  Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, all dates inclusive (the "Class Period"), have until Monday, August 10, 2026 to seek appointment as lead plaintiff of the ADMA Biologics class action lawsuit. Captioned Mazzarino v.

Jul 17, 2026 12:00 AM • prnewswire.com (Hide legal announcements)
INVESTOR DEADLINE: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

INVESTOR DEADLINE: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

San Diego, California--(Newsfile Corp. - July 16, 2026) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, inclusive (the "Class Period"), have until Monday, August 10, 2026 to seek appointment as lead plaintiff of the ADMA Biologics class action lawsuit. Captioned Mazzarino v.

Jul 16, 2026 04:50 PM • newsfilecorp.com (Hide legal announcements)
ADMA DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA

ADMA DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA

NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the “Class Period”), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

Jul 16, 2026 10:16 AM • globenewswire.com (Hide legal announcements)
NASDAQ: ADMA CLASS ACTION NOTICE: Berger Montague Encourages ADMA Biologics, Inc. (NASDAQ: ADMA) Investors to Inquire About a Securities Fraud Class Action

NASDAQ: ADMA CLASS ACTION NOTICE: Berger Montague Encourages ADMA Biologics, Inc. (NASDAQ: ADMA) Investors to Inquire About a Securities Fraud Class Action

PHILADELPHIA, July 16, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company") on behalf of investors who purchased or acquired ADMA common stock during the period from August 9, 2024 through March 25, 2026 (the "Class Period"). Investor Deadline: Investors who purchased or acquired ADMA securities during the Class Period may, no later than August 10, 2026 , seek to be appointed as a lead plaintiff representative of the class.

Jul 16, 2026 08:21 AM • prnewswire.com (Hide legal announcements)
ADMA Biologics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ADMA Biologics, Inc. - ADMA

ADMA Biologics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ADMA Biologics, Inc. - ADMA

NEW ORLEANS, July 16, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 10, 2026 to file lead plaintiff applications in a securities class action lawsuit against ADMA Biologics, Inc. (NasdaqGM: ADMA) (“ADMA” or the “Company”), if they purchased or otherwise acquired the Company's securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.

Jul 16, 2026 07:26 AM • globenewswire.com (Hide legal announcements)
ADMA DEADLINE: SueWallSt Reminds ADMA BIOLOGICS, INC. Investors of Upcoming Securities Class Action Deadline

ADMA DEADLINE: SueWallSt Reminds ADMA BIOLOGICS, INC. Investors of Upcoming Securities Class Action Deadline

ADMA Biologics allegedly certified internal controls as effective while concealing channel stuffing and an undisclosed related party distributor operating from company headquarters. NEW YORK, July 16, 2026 /PRNewswire/ -- SueWallSt alerts investors in ADMA Biologics, Inc. (NASDAQ: ADMA) of a pending securities class action.

Jul 16, 2026 06:09 AM • prnewswire.com (Hide legal announcements)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming Deadlines - ADMA

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming Deadlines - ADMA

NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

Jul 16, 2026 06:00 AM • prnewswire.com (Hide legal announcements)
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ADMA Biologics, Inc. (ADMA)

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ADMA Biologics, Inc. (ADMA)

NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, inclusive. Should You Join The ADMA Class Action Lawsuit : Do you, or did you, own shares of ADMA Biologics, Inc. (NASDAQ: ADMA)?

Jul 16, 2026 05:16 AM • globenewswire.com (Hide legal announcements)
ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES, July 15, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). IF YOU SUFFERED A LOSS ON YOUR ADMA INVESTMENTS, CLICK  HERE  BEFORE AUGUST 10, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?

Jul 15, 2026 11:24 AM • prnewswire.com (Hide legal announcements)
ADMA INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

ADMA INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ADMA Biologics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ADMA Biologics between August 9, 2024 and March 25, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - July 15, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ADMA Biologics, Inc. ("ADMA Biologics" or the "Company") (NASDAQ: ADMA) and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Jul 15, 2026 09:18 AM • newsfilecorp.com (Hide legal announcements)
ROSEN, A LEADING LAW FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ADMA

ROSEN, A LEADING LAW FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ADMA

New York, New York--(Newsfile Corp. - July 15, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased ADMA Biologics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Jul 15, 2026 08:42 AM • newsfilecorp.com (Hide legal announcements)
ADMA Shareholder Alert: ADMA BIOLOGICS, INC. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

ADMA Shareholder Alert: ADMA BIOLOGICS, INC. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

Three senior officers of ADMA Biologics personally certified financial statements that allegedly concealed a channel stuffing scheme and undisclosed related party transactions, exposing them to individual liability under federal securities law. NEW YORK, July 15, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP alerts investors in ADMA Biologics, Inc. (NASDAQ: ADMA) of a pending securities class action naming senior executives as individual defendants.

Jul 15, 2026 06:07 AM • prnewswire.com (Hide legal announcements)
$ADMA Investor Loss Alert: ADMA Biologics Investors may have been Misled after Channel Stuffing Claims Lead to 29% Stock Drop – Contact BFA Law if You Lost Money

$ADMA Investor Loss Alert: ADMA Biologics Investors may have been Misled after Channel Stuffing Claims Lead to 29% Stock Drop – Contact BFA Law if You Lost Money

NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm  Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ:ADMA) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.

Jul 15, 2026 02:17 AM • globenewswire.com (Hide legal announcements)
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

NEW YORK and NEW ORLEANS, July 14, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. (“ADMA” or the “Company”) (NasdaqGM: ADMA) of a class action securities lawsuit.

Jul 14, 2026 06:41 PM • globenewswire.com (Hide legal announcements)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming Deadlines – ADMA

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming Deadlines – ADMA

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA).   Such investors are advised to contact Danielle Peyton at  [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Jul 14, 2026 01:30 PM • globenewswire.com (Hide legal announcements)
ROSEN, A LEADING LAW FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ADMA

ROSEN, A LEADING LAW FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ADMA

New York, New York--(Newsfile Corp. - July 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased ADMA Biologics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Jul 14, 2026 08:37 AM • newsfilecorp.com (Hide legal announcements)

Price Targets